Market research
MIR.V MedMira Inc
V CAD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 42M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.78
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA58501R1029
- Market cap
- 42M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.78
About
About MedMira Inc
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
Research context
MedMira Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MIR.V discussion.
5 years, 6 months ago
MedMira Inc is currently in a long term downtrend where the price is trading 44.7% below its 200 day moving average.
From a valuation standpoint, the stock is 93.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 67.7.
MedMira Inc's total revenue rose by 1587.0% to $2M since the same quarter in the previous year.
Its net income has increased by 216.4% to $715K since the same quarter in the previous year.
Finally, its free cash flow grew by 11.8% to $-363K since the same quarter in the previous year.
Based on the above factors, MedMira Inc gets an overall score of 4/5.